Browse drugs

…levels, suggestive of a tumor response to treatment.Conclusions STAR0602 induces dynamic immune activation, promoting the potent and sel…

… van Laarhoven HWM. Neoadjuvant chemoradiotherapy combined with atezolizumab for resectable esophageal adenocarcinoma: a single-arm phase II…

…city, and expansion. To develop an off-the-shelf treatment with WAY-102, we used an engineered lentivirus for in vivo CAR T manufacturi…

…n expanded multi-trial meta-cohort of 586 patients treated with axi-cel. Product characterization was performed with scRNAseq and scATA…

…st BCMA-negative HMC3 cells. In contrast, our novel CAR T-cell, LTG3551, exhibited low tonic signaling, compelling anti-tumor activity,…

…Y-ESO-1 expression, baseline ECOG 0–1, and received any dose of lete-cel. Treatment-naïve patients (SyS, n=5) were excluded from the eff…

…age small cell lung cancer. Oncologist 2021;26:433-8.Imdelltra (tarlatamab). Full Prescribing Information, Amgen Inc, Thousand Oaks, CA, U…

…o TIGIT-expressing cells, even in mixed populations.Conclusions Rilvegostomig’s potent, preferential TIGIT binding and cooperative PD-1 engag…

…mFOLFOX6 plus atezolizumab 840 mg Q2W for 12 cycles followed by atezolizumab monotherapy Q3W for 13 cycles (experimental). The primary end-p…

…nuclear cells (PBMCs) were collected from NHL patients prior to NKX019 infusion. Single cell transcriptome and paired TCR sequencing w…

… Group performance status of 0 or 1. Eligible patients received tislelizumab (200 mg, IV Q3W) or sintilimab (200 mg, IV Q3W) for a lead-in p…

…ing.Conclusions Preliminary dose escalation data are promising. BI-1910 monotherapy shows a favorable safety and tolerability profile, …